Abstract:Background: A fixed combination of formoterol, glycopyrrolate, and beclomethasone dipropionate is approved in some geographic areas as pressurized metered dose inhaler (pMDI) formulation for the treatment of asthma and chronic obstructive pulmonary disease. Current pMDIs use hydrofluoroalkanes (HFAs) as a propellant, such as 1,1,1,2-tetrafluoroethane (HFA134a), that have a high global warming potential (GWP), but their use is being progressively lowered to reduce impact on climate. One option to reduce the carbon footprint of the pMDI products while preserving pMDIs as a therapeutic option is reformulating the current pMDIs using low GWP propellants, such as 1,1-difluoroethane (HFA152a). Nevertheless, pharmaceutical, clinical, and regulatory challenges need to be considered when reformulating a pMDI. A nonclinical study in rodents has been performed to support the formulation work and optimize the design of the bioequivalence study in humans. Methods: A fixed combination of formoterol, glycopyrrolate, and beclomethasone dipropionate (BDP) as pMDI with the two propellants HFA134a or HFA152a was administered by inhalation to Sprague-Dawley rats, using inhalation tower, to assess the impact of the propellant on the PK profile of the active components. After administration, serial blood samples were taken from each rat, and plasma aliquots were analyzed by HPLC-MS/MS. Results: Inhalation administration to rats of the fixed triple combination as pMDI showed similar PK profile for formoterol, glycopyrrolate, and BDP with the two propellants. Exposure parameters Cmax and AUClast of the three active ingredients were compared, showing no statistically significant differences in the systemic exposure between the two treatment groups. Higher interanimal variability was observed for the metabolite beclomethasone 17-monopropionate, likely due to individual differences in the metabolite generation. Conclusions: Considering these data, it was possible to conclude that replacing propellant HFA134a with HFA152a in a newly developed formulation had no significant impact on the plasmatic PK profile of formoterol, glycopyrrolate, and BDP in rats after inhalation administration using inhalation towers.

Determination of reference ultrasound parameters for model and hydrofluoroalkane propellants using high-resolution ultrasonic spectroscopy

Measurement of Saturated Vapor Pressure and Compressed Liquid Density for 1,1,1,3,3,3-Hexafluoroisopropylmethyl Ether

An experimental study of PVTx properties in the gas phase for binary mixtures of HFO-1234yf and HFC-134a

Understanding the performance of pressurized metered dose inhalers formulated with low Global warming potential propellants

In vitro evaluation of solution-based pressurised metered dose inhaler sprays with low GWP propellants

An Experimental Study of PVTx Properties in the Gas Phase for Binary Mixtures of HFC-161 and HFC-32

Experimental Investigation of Vapor–Liquid Equilibrium for 2,3,3,3-Tetrafluoropropene (Hfo-1234Yf) + Trans-1,3,3,3-tetrafluoropropene (Hfo-1234Ze(e)) at Temperatures from 284 to 334 K

Canister valve and actuator deposition in metered dose inhalers formulated with low-GWP propellants

Measurement of the Raman spectra and hygroscopicity of four pharmaceutical aerosols as they travel from pressurised metered dose inhalers (pMDI) to a model lung

Comparison of Formoterol, Glycopyrrolate, and Beclomethasone Dipropionate Pharmacokinetic Profile after Inhaled Administration as pMDI Using HFA134a or HFA152a Propellant: Preclinical Assessment of Drug Exposure in Sprague-Dawley Rat Model

Speed of Sound Measurements and Correlation of {x 3,3,3-Trifluoropropene (HFO-1243zf) + (1−x)2,3,3,3-tetrafluoropropene (HFO-1234yf)} with x = (0.2856, 0.5054, 0.8418) at Temperatures from 243.15 K to 348.15 K and Pressures up to 90 MPa

Vapor−Liquid Equilibrium Data for the Binary Mixture Difluoroethane (HFC-32) + Pentafluoroethane (HFC-125) of an Alternative Refrigerant

A force field for 3,3,3-fluoro-1-propenes, including HFO-1234yf

Solubilities of R32, R245fa, R227ea and R236fa in a Phosphonium-Based Ionic Liquid

All-atom force field for the prediction of vapor-liquid equilibria and interfacial properties of HFA134a

Vapor Pressures of 1,1,1,3,3-Pentafluoropropane (Hfc-245Fa) and 1,1,1,2,3,3,3-Heptafluoropropane (Hfc-227Ea)

Surface tension measurements of 1,1,1,3,3-pentafluoropropane (HFC-245fa) and 1,1,1,3,3,3-hexafluoropropane (HFC-236fa) from 254 to 333 K

Measurement of Speed of Sound with a Spherical Resonator: HCFC-22, HFC-152a, HFC-143a, and Propane

Vapor pressures of 1,1,1,2,3,3,3-heptafluoropropane, 1,1,1,3,3,3-hexafluoropropane and 1,1,1,3,3-pentafluoropropane

On the Feasibility of Rugose Lipid Microparticles in Pressurized Metered Dose Inhalers with Established and New Propellants

Correlation Between Dynamic Spray Plume and Drug Deposition of Solution-Based Pressurized Metered-Dose Inhalers